Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | PNMT | P11086 | 6/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | HTR2B | P41595 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30519224 | 1.00 | ASIC3 (0.48) | ASIC3PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL29950479 | 0.99 | ASIC3 (0.47) | ASIC3PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL25429072 | 0.99 | ASIC3 (0.47) | ASIC3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29950645 | 0.87 | PDE4A (0.45) | ASIC3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29808272 | 0.82 | ASIC3 (0.60) | ASIC3PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL183621 | 0.82 | ASIC3 (0.60) | ASIC3PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL29098086 | 0.82 | MAOB (0.55) | HRH3 | |
| SCHEMBL30199485 | 0.82 | MAOB (0.55) | HRH3 | |
| SCHEMBL25341658 | 0.82 | PNMT (0.42) | ASIC3PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL30519156 | 0.82 | PNMT (0.42) | ASIC3PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129028-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-04-24 | — | — | US | disclosed |
| WO-2023147063-A2 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147063-A2 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129028-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | YAP1, YES1, LATS1 | ASIC3 2217/4885PDE4A 2801/4885PDE4B 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.